A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate, Carlos A., Singh, Jaskaran B., Carlson, Paul J., Brutsche, Nancy E., Ameli, Rezvan, Luckenbaugh, David A., Charney, Dennis S., Manji, Husseini K.·2006·Archives of General Psychiatry
DOI 10.1001/archpsyc.63.8.856

Cited by (1,095)

Items 801–900 of 1,095

  1. S-Ketamine Reverses Hippocampal Dendritic Spine Deficits in Flinders Sensitive Line Rats Within 1 h of Administration
    Treccani, Giulia, Ardalan, Maryam, Chen, Fenghua, Musazzi, Laura, Popoli, Maurizio, Wegener, Gregers, Nyengaard, Jens Randel, Müller, Heidi Kaastrup · 2019 · Molecular Neurobiology
  2. Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation
    Jessica R. Gilbert, Carlos A. Zarate · 2020 · Pharmacology Biochemistry and Behavior
  3. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
    Anees Bahji, Carlos A. Zarate, Gustavo Héctor Vázquez · 2022 · Expert Opinion on Drug Safety
  4. Elevated spectroscopic glutamate/&ggr;-amino butyric acid in rats bred for learned helplessness
    A. Sartorius, Magdalena M. Mahlstedt, B. Vollmayr, F. Henn, G. Ende · 2007 · NeuroReport
  5. Trehalose induced antidepressant-like effects and autophagy enhancement in mice
    N. Kara, Lilah Toker, Galila Agam, Grant W. Anderson, R.H. Belmaker, Haim Einat · 2013 · Psychopharmacology
  6. Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: A PET Study in Conscious Monkeys
    Shigeyuki Yamamoto, Hiroyuki Ohba, Shingo Nishiyama, Norihiro Harada, Takeharu Kakiuchi, Hideo Tsukada, Edward F. Domino · 2013 · Neuropsychopharmacology
  7. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression
    Michael Liebrenz, Rudolf Stohler, Alain Borgeat · 2008 · The World Journal of Biological Psychiatry
  8. The nucleus accumbens: a target for deep brain stimulation in resistant major depressive disorder
    Cécilia Nauczyciel, Suzanne Robic, Thibaut Dondaine, Marc Vérin, Gabriel Robert, Dominique Drapier, Florian Naudet, Bruno Millet · 2013 · Journal of Molecular Psychiatry
  9. Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation
    Maria Giese, Jürgen Beck, Serge Brand, F. Muheim, Ulrich Hemmeter, Martin Hatzinger, Edith Holsboer‐Trachsler, Anne Eckert · 2014 · Journal of Psychiatric Research
  10. International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets
    Filippo Caraci, Francesca Calabrese, Raffaella Molteni, Lucie Bartova, Markus Dold, Gian Marco Leggio, Chiara Fabbri, Julien Mendlewicz, Giorgio Racagni, Siegfried F. Kasper et al. · 2018 · Pharmacological Reviews
  11. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression
    Zhou, Yanling, Zheng, Wei, Liu, Weijian, Wang, Chengyu, Zhan, Yanni, Li, Hanqiu, Chen, Lijian, Li, Mingding, Ning, Yuping · 2018 · Journal of Psychopharmacology
  12. Propofol for Treatment-Resistant Depression: A Pilot Study
    Mickey, Brian J, White, Andrea T, Arp, Anna M, Leonardi, Kolby, Torres, Marina M, Larson, Adam L, Odell, David H, Whittingham, Sara A, Beck, Michael M, Jessop, Jacob E et al. · 2018 · International Journal of Neuropsychopharmacology
  13. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
    Salahudeen, Mohammed S, Wright, Cameron M, Peterson, Gregory M · 2020 · Therapeutic Advances in Drug Safety
  14. Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: Preventive effect of lurasidone treatment during adolescence
    Alessia Luoni, Alessandra Berry, Francesca Calabrese, Sara Capoccia, Veronica Bellisario, Peter Gass, Francesca Cirulli, Marco Andrea Riva · 2014 · European Neuropsychopharmacology
  15. Emerging targets for antidepressant therapies
    Jeffrey J. Rakofsky, Paul E. Holtzheimer, Charles B. Nemeroff · 2009 · Current Opinion in Chemical Biology
  16. Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress
    Millie Rincón‐Cortés, Anthony A. Grace · 2019 · Behavioural Brain Research
  17. THERAPEUTIC MECHANISMS OF KETAMINE
    Slobodan Mihaljević, Matko Pavlović, Kresimir Reine, Marko Čačić · 2020 · Psychiatria Danubina
  18. A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties
    Rachael L. Sumner, Emme Chacko, Rebecca L. McMillan, Meg J. Spriggs, Christie Anderson, James Chen, Amelia French, Sunghun Jung, Akshaya Rajan, Gemma A. Malpas et al. · 2021 · Journal of Psychopharmacology
  19. Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: An 11.7T 1H-MRS study in rats
    Shane Alan Perrine, Farhad Ghoddoussi, Mark S. Michaels, Imran S. Sheikh, George M. McKelvey, Matthew P. Galloway · 2013 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  20. An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets
    Kanwaljit Chopra, Vipin K Arora · 2013 · Expert Opinion on Therapeutic Targets
  21. Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test
    Yan Li, Zhuo R. Zhu, Bao C. Ou, Ya Q. Wang, Zhou B. Tan, Chang M. Deng, Yi Gao, Ming Tang, Ji H. So, Yangling Mu et al. · 2014 · Behavioural Brain Research
  22. Corticotropin-Releasing Hormone, Glutamate, and γ-Aminobutyric Acid in Depression
    Shangfeng Gao, Ai‐Min Bao · 2010 · The Neuroscientist
  23. Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
    Joshua Daniel Rosenblat, Roger S. McIntyre, Gilberto Sousa Alves, Konstantinos Ν. Fountoulakis, Andre Ferrer Carvalho · 2015 · Current Neuropharmacology
  24. Behavioral and biochemical sensitivity to low doses of ketamine: Influence of estrous cycle in C57BL/6 mice
    Amanda M. Dossat, Katherine N. Wright, Caroline E. Strong, Mohamed Kabbaj · 2017 · Neuropharmacology
  25. Proteomic Enrichment Analysis of Psychotic and Affective Disorders Reveals Common Signatures in Presynaptic Glutamatergic Signaling and Energy Metabolism
    Michael G. Gottschalk, Hendrik Wesseling, Paul C. Guest, Sabine Bahn · 2015 · The International Journal of Neuropsychopharmacology
  26. Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
    Naghmeh Nikkheslat · 2021 · Brain Behavior & Immunity - Health
  27. Structural neural plasticity evoked by rapid-acting antidepressant interventions
    Clara Liao, Alisha N. Dua, Cassandra Wojtasiewicz, Conor M. Liston, Alex C. Kwan · 2024 · Nature reviews. Neuroscience
  28. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response‐related difference in mitochondrial networks
    Villaseñor, A, Ramamoorthy, A, Silva dos Santos, M, Lorenzo, M P, Laje, G, Zarate, C, Barbas, C, Wainer, I W · 2014 · British Journal of Pharmacology
  29. Ketamine, magnesium and major depression – From pharmacology to pathophysiology and back
    Harald Murck · 2013 · Journal of Psychiatric Research
  30. Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress
    Gislaine Tezza Rezin, Cinara Ludvig Gonçalves, Juliana Felipe Daufenbach, Daiane B. Fraga, P.M.L. Santos, Gabriela Kozuchovski Ferreira, Fernanda V. Hermani, Clarissa Martinelli Comim, João Quevedo, Emilio Luiz STRECK · 2009 · Brain Research Bulletin
  31. Attenuation of Reserpine-Induced Pain/Depression Dyad by Gentiopicroside Through Downregulation of GluN2B Receptors in the Amygdala of Mice
    Shui‐bing Liu, Rong Zhao, Xusheng Li, Hong-ju Guo, Zhen Tian, Nan Zhang, Guodong Gao, Ming Zhao · 2014 · NeuroMolecular Medicine
  32. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome
    Sandra P. Koffler, Benjamin M. Hampstead, Farzin Irani, J TINKER, R. T. Kiefer, Peter Rohr, Robert J. Schwartzman · 2007 · Archives of Clinical Neuropsychology
  33. Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder
    Bashkim Kadriu, Philip W. Gold, David A. Luckenbaugh, Marc S. Lener, Elizabeth D. Ballard, Mark J. Niciu, Ioline D. Henter, Lawrence T. Park, R T De Sousa, P Yuan et al. · 2017 · Molecular Psychiatry
  34. Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder
    Rachael L. Sumner, Rebecca L. McMillan, Meg J. Spriggs, Doug A. Campbell, Gemma A. Malpas, Elizabeth Maxwell, Carolyn Deng, John Hay, Rhys Ponton, Ian J. Kirk et al. · 2019 · Biological Psychiatry Cognitive Neuroscience and Neuroimaging
  35. MicroRNA expression profile and functional analysis reveal that miR-206 is a critical novel gene for the expression of BDNF induced by ketamine.
    Yang, Xiaolin, Yang, Qinyan, Wang, Xiaobin, Luo, Chunqiong, Wan, Yunqiang, Li, Jiali, Liu, Kezhi, Zhou, Min, Zhang, Chunxiang · 2014 · NeuroMolecular Medicine
  36. Ketamine Influences CLOCK:BMAL1 Function Leading to Altered Circadian Gene Expression
    Bellet, Marina M., Vawter, Marquis P., Bunney, Blynn G., Bunney, William E., Sassone-Corsi, Paolo · 2011 · PLoS ONE
  37. Is There Anything Really Novel on the Antidepressant Horizon?
    James W. Murrough, Dennis S. Charney · 2012 · Current Psychiatry Reports
  38. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach
    Rodrigo Machado‐Vieira, Márcio Gerhardt Soeiro‐de‐Souza, Erica M. Richards, Antônio Lúcio Teixeira, Carlos A. Zarate · 2013 · The World Journal of Biological Psychiatry
  39. Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
    Yating Wang, Xiaole Wang, Sitong Feng, Nai‐Hong Chen, Zhen‐Zhen Wang, Yi Zhang · 2021 · Pharmacological Research
  40. A Systematic Review of Ketamine for Complex Regional Pain Syndrome
    S. Connolly, Joshua P. Prager, Robert Norman Harden · 2015 · Pain Medicine
  41. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era
    Noah S. Philip, Linda L. Carpenter, Audrey R. Tyrka, Lawrence H. Price · 2010 · Expert Opinion on Pharmacotherapy
  42. Long-Term Maintenance With Intramuscular Ketamine for Treatment-Resistant Bipolar II Depression
    Cristina Cusin, George Q. Hilton, Andrew Alan Nierenberg, Maurizio Fava M. D · 2012 · American Journal of Psychiatry
  43. Synaptic Regulation of a Thalamocortical Circuit Controls Depression-Related Behavior
    Oliver H Miller, Andreas Bruns, Imen Ben Ammar, Thomas Mueggler, Benjamin J. Hall · 2017 · Cell Reports
  44. Esketamine: a glimmer of hope in treatment-resistant depression
    Upinder Kaur, Bhairav Kumar Pathak, Amit Singh, Sankha Shubhra Chakrabarti · 2019 · European Archives of Psychiatry and Clinical Neuroscience
  45. Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression
    Kaut, Oliver, Schmitt, Ina, Hofmann, Andrea, Hoffmann, Per, Schlaepfer, Thomas E., Wüllner, Ullrich, Hurlemann, René · 2015 · European Archives of Psychiatry and Clinical Neuroscience
  46. Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms
    Hare, Brendan D., Ghosal, Sriparna, Duman, Ronald S. · 2017 · Chronic Stress
  47. Ketamine suppresses proliferation and induces ferroptosis and apoptosis of breast cancer cells by targeting KAT5/GPX4 axis
    Huixin Li, Wei Liu, Xiaoyu Zhang, Feng Wu, Dan Sun, Zunyi Wang · 2021 · Biochemical and Biophysical Research Communications
  48. Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro
    Senem Merve Fred, Suvi H. Kuivanen, Hasan Uğurlu, Plinio Cabrera Casarotto, Lev Levanov, Kalle Saksela, Olli P. Vapalahti, Eero Ċastrén · 2022 · Frontiers in Pharmacology
  49. Gray colored glasses: Is major depression partially a sensory perceptual disorder?
    Paul J. Fitzgerald · 2013 · Journal of Affective Disorders
  50. Augmentation Strategies in Electroconvulsive Therapy
    Colleen K A Loo, Brett Simpson, Ross MacPherson · 2010 · Journal of Ect
  51. A preclinical and clinical rationale for quetiapine in mood syndromes
    Roger S. McIntyre, Joanna K. Soczynska, Hanna O. Woldeyohannes, Mohammad T. Alsuwaidan, Jakub Z. Konarski · 2007 · Expert Opinion on Pharmacotherapy
  52. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
    Doherty, Teodora, Wajs, Ewa, Melkote, Rama, Miller, Janice, Singh, Jaskaran B., Weber, Michael A. · 2020 · CNS Drugs
  53. Ketamine normalizes brain activity during emotionally valenced attentional processing in depression
    Reed, Jessica L., Nugent, Allison C., Furey, Maura L., Szczepanik, Joanna E., Evans, Jennifer W., Zarate, Carlos A. · 2018 · NeuroImage: Clinical
  54. Cognition as a target in major depression: new developments.
    Solé, Brisa, Jiménez, Esther, Martinez-Aran, Anabel, Vieta, Eduard · 2015 · European Neuropsychopharmacology
  55. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine
    Briana K. Chen, Victor M. Luna, Christina T. LaGamma, Xiaoming Xu, Shi‐Xian Deng, Raymond F. Suckow, Thomas B. Cooper, Abhishek Shah, Rebecca A. Brachman, Indira Mendez‐David et al. · 2020 · Neuropsychopharmacology
  56. Palliative Care Psychiatry: Update on an Emerging Dimension of Psychiatric Practice
    Nathan Paul Fairman, Scott A. Irwin · 2013 · Current Psychiatry Reports
  57. Antidepressant-like effect of folic acid: Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway
    Patrícia S. Brocardo, Josiane Budni, Kelly R. Lobato, Manuella Pinto Kaster, Ana Lúcia S. Rodrigues · 2008 · European Journal of Pharmacology
  58. Increased Response to Ketamine Following Treatment at Long Intervals: Implications for Intermittent Use
    Keith A. Trujillo, Juan J. Zamora, Kathleen P. Warmoth · 2007 · Biological Psychiatry
  59. Antidepressant-like effect of α-tocopherol in a mouse model of depressive-like behavior induced by TNF-α
    Luana Meller Manosso, Vivian Binder Neis, Morgana Moretti, Juliana Felipe Daufenbach, Andiara E. Freitas, André Roberto Da Silva Colla, Ana Lúcia S. Rodrigues · 2013 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  60. Involvement of nitric oxide–cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test
    Morgana Moretti, Andiara E. Freitas, Josiane Budni, Sinara Castellen Pereira Fernandes, Grasiela O. Balen, Ana Lúcia S. Rodrigues · 2011 · Behavioural Brain Research
  61. Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype
    Demitri F. Papolos, Martin H. Teicher, Gianni L. Faedda, Patricia Murphy, Steven A. Mattis · 2012 · Journal of Affective Disorders
  62. Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats
    Mariusz Papp, Piotr Gruca, Magdalena Łasoń, Paul Willner · 2016 · Psychopharmacology
  63. A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting
    John Burger, Marc Capobianco, Robert Lovern, Ben Boche, Elliot M Ross, Michael A. Darracq, Robert N. McLay · 2016 · Military Medicine
  64. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder
    Sabine Aust, Matti Gärtner, Laura Basso, Christian Otte, Katja Wingenfeld, Woo Ri Chae, Isabella Heuser, Francesca Regen, Nicoleta Carmen Cosma, Franziska van Hall et al. · 2019 · European Neuropsychopharmacology
  65. Loss of phenotype of parvalbumin interneurons in rat prefrontal cortex is involved in antidepressant- and propsychotic-like behaviors following acute and repeated ketamine administration
    Zhou, ZhiQiang, Zhang, GuangFen, Li, XiaoMin, Liu, XiaoYu, Wang, Nan, Qiu, LiLi, Liu, WenXue, Zuo, ZhiYi, Yang, JianJun · 2015 · Molecular Neurobiology
  66. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes
    Antonio Drago, Concetta Crisafulli, Antonina Sidoti, Alessandro Serretti · 2011 · Progress in Neurobiology
  67. A Review of Nonanesthetic Uses of Ketamine
    Abby M. Pribish, Nicole J. Wood, Arun Kalava · 2020 · Anesthesiology Research and Practice
  68. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
    Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, Jessica R. Gilbert, Ioline D. Henter, Carlos A. Zarate · 2023 · Neuropharmacology
  69. Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications
    Francesco Weiss, Anna Magnesa, Matteo Gambini, Riccardo Gurrieri, Eric Annuzzi, Camilla Elefante, Giulio Perugi, Donatella Marazziti · 2025 · Brain Sciences
  70. Large-Scale Persistent Network Reconfiguration Induced by Ketamine in Anesthetized Monkeys: Relevance to Mood Disorders
    Qian Lv, Liqin Yang, Guoliang Li, Zhiwei Wang, Zhuangming Shen, Wenwen Yu, Qinying Jiang, Baoyu Hou, Jian Pu, Hailan Hu et al. · 2015 · Biological Psychiatry
  71. Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain
    Juan M. Lima‐Ojeda, Miriam Annika Vogt, Natascha Pfeiffer, Christof Dormann, Georg Köhr, Rolf Sprengel, Peter Gass, Dragoš Inta · 2013 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  72. The effects of brain serotonin deficiency on behavioural disinhibition and anxiety-like behaviour following mild early life stress
    Benjamin D. Sachs, Ramona M. Rodriguiz, William B. Siesser, Alexander Kenan, Elizabeth L. Royer, Jacob P. R. Jacobsen, William C. Wetsel, Marc G. Caron · 2013 · The International Journal of Neuropsychopharmacology
  73. Neurobiology of bipolar disorder
    Andrew R Newberg, Lisa A. Catapano, Carlos A. Zarate, Husseini K. Manji · 2007 · Expert Review of Neurotherapeutics
  74. (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism
    Riggs, Lace M., Aracava, Yasco, Zanos, Panos, Fischell, Jonathan, Albuquerque, Edson X., Pereira, Edna F. R., Thompson, Scott M., Gould, Todd D. · 2020 · Neuropsychopharmacology
  75. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study
    Taylor, Matthew J, Tiangga, Eleanor R, Mhuircheartaigh, Roísín Ní, Cowen, Philip J · 2012 · Journal of Psychopharmacology
  76. Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: Involvement of nitric oxide
    Pereira, Vitor S., Casarotto, Plinio C., Hiroaki-Sato, Vinícius A., Sartim, Ariandra G., Guimarães, Francisco S., Joca, Sâmia R.L. · 2013 · European Neuropsychopharmacology
  77. Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities
    Meng Li, Liliana Ramona Demenescu, Lejla Čolić, Coraline D. Metzger, Hans‐Jochen Heinze, Johann Steiner, Oliver Speck, Anna Fejtová, Giacomo Salvadore, Martin Walter · 2016 · Neuropsychopharmacology
  78. Conceptualizing anhedonias and implications for depression treatments
    E. Samuel Winer, D. Gage Jordan, Amanda C Collins · 2019 · Psychology Research and Behavior Management
  79. The emergence of ketamine as a novel treatment for posttraumatic stress disorder
    Adriana Feder, Sarah Rutter, Daniela Schiller, Dennis S. Charney · 2020 · Advances in pharmacology
  80. Culture and psychedelic psychotherapy: Ethnic and racial themes from three Black women therapists
    Monnica T. Williams, Sara Reed, Jamilah R. George · 2020 · Journal of Evolutionary Psychology
  81. Ketamine and its metabolites: Potential as novel treatments for depression
    Kai Zhang, Yitan Yao, Kenji Hashimoto · 2022 · Neuropharmacology
  82. Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series
    Georgios Paslakis, Morin Gilles, Andreas Meyer‐Lindenberg, Michael Deuschle · 2009 · Pharmacopsychiatry
  83. Shaping the renaissance of psychedelic research
    Ben Sessa · 2012 · The Lancet
  84. The Mood Stabilizer Lithium Potentiates the Antidepressant-Like Effects and Ameliorates Oxidative Stress Induced by Acute Ketamine in a Mouse Model of Stress
    Chi‐Tso Chiu, Lisa Scheuing, Guangping Liu, Hsiao‐Mei Liao, Gabriel R. Linares, Dora H. Lin, De‐Maw Chuang · 2015 · The International Journal of Neuropsychopharmacology
  85. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double‐blind, randomized, placebo‐controlled trial
    Amit Anand, Abigail D. Gunn, Gavriel Barkay, Harish S. Karne, John I. Nürnberger, Sanjay J. Mathew, Samiran Ghosh · 2012 · Bipolar Disorders
  86. Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics
    Oleg I. Barygin, Elina I. Nagaeva, Denis B. Tikhonov, Darya A. Belinskaya, Nina Pavlovna Vanchakova, Natalia N. Shestakova · 2017 · Brain Research
  87. Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder
    Vande Voort, Jennifer L., Ballard, Elizabeth D., Luckenbaugh, David A., Bernert, Rebecca A., Richards, Erica M., Niciu, Mark J., Park, Lawrence T., Machado-Vieira, Rodrigo, Duncan, Wallace C., Zarate, Carlos A. · 2017 · The Journal of Clinical Psychiatry
  88. Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine
    Gärtner, Matti, Aust, Sabine, Bajbouj, Malek, Fan, Yan, Wingenfeld, Katja, Otte, Christian, Heuser-Collier, Isabella, Böker, Heinz, Hättenschwiler, Josef, Seifritz, Erich et al. · 2019 · European Neuropsychopharmacology
  89. Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action
    Du, Jing, Machado-Vieira, Rodrigo, Maeng, Sungho, Martinowich, Keri, Manji, Husseini K., Zarate, Carlos A. · 2006 · Drug Discovery Today: Therapeutic Strategies
  90. Antidepressant mechanism of ketamine: perspective from preclinical studies
    Lisa Scheuing, Chi‐Tso Chiu, Hsiao‐Mei Liao, De‐Maw Chuang · 2015 · Frontiers in Neuroscience
  91. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression
    Rei Yokoyama, Momoko Higuchi, Wataru Tanabe, Shinji Tsukada, Megumi Naito, Takumi Yamaguchi, Lu Chen, Atsushi Kasai, Kaoru Seiriki, Takanobu Nakazawa et al. · 2020 · Pharmacology Biochemistry and Behavior
  92. Ketamine for Bipolar Depression: A Systematic Review
    Anees Bahji, Carlos A. Zarate, Gustavo Héctor Vázquez · 2021 · The International Journal of Neuropsychopharmacology
  93. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
    Guang Chen, Li Chen, Yun Zhang, Xiang Li, R. Lane, P. Lim, Ella J. Daly, M. Furey, M. Fedgchin, V. Popova et al. · 2022 · International Journal of Neuropsychopharmacology
  94. A unified model of ketamine’s dissociative and psychedelic properties
    M. Marguilho, I. Figueiredo, Pedro Castro-Rodrigues · 2022 · Journal of Psychopharmacology
  95. Repeated S‐ketamine Infusions in Therapy Resistant Depression: A Case Series
    Felix Maximilian Segmiller, Tobias Rüther, Andrea Linhardt, Frank Padberg, Michael Berger, Oliver Michael Pogarell, Hans‐Jürgen Möller, Christina Kohler, Cornelius Schüle · 2013 · The Journal of Clinical Pharmacology
  96. Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats
    Hiroyuki Koike, Michihiko Iijima, Shigeyuki Chaki · 2013 · Pharmacology Biochemistry and Behavior
  97. Maternal Care Influences Hippocampal N-Methyl-D-Aspartate Receptor Function and Dynamic Regulation by Corticosterone in Adulthood
    Bagot, Rosemary C., Tse, Yiu Chung, Nguyen, Huy-Binh, Wong, Alice S., Meaney, Michael J., Wong, Tak Pan · 2012 · Biological Psychiatry
  98. NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice
    Mohammad Salehi-Sadaghiani, Mehrak Javadi Paydar, Mohammad Hadi Gharedaghi, Ali Zandieh, Pouria Heydarpour, Yashar Yousefzadeh-fard, Ahmad Reza Dehpour · 2012 · Psychopharmacology
  99. GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine
    J. Kiss, Bernadett K. Szász, László Fodor, Árpád Mike, Nora Lenkey, Dalma Kurkó, József Nagy, E. Sylvester Vizi · 2011 · Neurochemistry International
  100. Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications
    Melvyn W. Zhang, Keith M. Harris, Roger Ho · 2016 · BMC Medical Ethics